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Research Article
Biochemical and transcript level differences
between the three human phosphofructokinases
show optimisation of each isoform for specific
metabolic niches
Peter M. Fernandes, James Kinkead, Iain McNae, Paul A.M. Michels and Malcolm D. Walkinshaw
School of Biological Sciences, University of Edinburgh, Michael Swann Building, Max Born Crescent, Edinburgh EH9 3BF, U.K.
Correspondence: Malcolm D. Walkinshaw: M.Walkinshaw@ed.ac.uk
6-Phosphofructokinase-1-kinase (PFK) tetramers catalyse the phosphorylation of fructose
6-phosphate (F6P) to fructose 1,6-bisphosphate (F16BP). Vertebrates have three PFK iso-
forms (PFK-M, PFK-L, and PFK-P). This study is the first to compare the kinetics, struc-
tures, and transcript levels of recombinant human PFK isoforms. Under the conditions
tested PFK-M has the highest affinities for F6P and ATP (K0.5
ATP 152 mM; K0.5
F6P 147 mM),
PFK-P the lowest affinities (K0.5
ATP 276 mM; K0.5
F6P 1333 mM), and PFK-L demonstrates a
mixed picture of high ATP affinity and low F6P affinity (K0.5
ATP 160 mM; K0.5
F6P 1360 mM).
PFK-M is more resistant to ATP inhibition compared with PFK-L and PFK-P (respectively,
23%, 31%, 50% decreases in specificity constants). GTP is an alternate phospho donor.
Interface 2, which regulates the inactive dimer to active tetramer equilibrium, differs
between isoforms, resulting in varying tetrameric stability. Under the conditions tested
PFK-M is less sensitive to fructose 2,6-bisphosphate (F26BP) allosteric modulation than
PFK-L or PFK-P (allosteric constants [K0.5
ATP+F26BP/K0.5
ATP] 1.10, 0.92, 0.54, respectively).
Structural analysis of two allosteric sites reveals one may be specialised for AMP/ADP
and the other for smaller/flexible regulators (citrate or phosphoenolpyruvate). Correlations
between PFK-L and PFK-P transcript levels indicate that simultaneous expression may
expand metabolic capacity for F16BP production whilst preserving regulatory capabilities.
Analysis of cancer samples reveals intriguing parallels between PFK-P and PKM2 (pyru-
vate kinase M2), and simultaneous increases in PFK-P and PFKFB3 (responsible for
F26BP production) transcript levels, suggesting prioritisation of metabolic flexibility in
cancers. Our results describe the kinetic and transcript level differences between the
three PFK isoforms, explaining how each isoform may be optimised for distinct roles.
Introduction
6-Phosphofructokinase-1-kinase (PFK) (EC 2.7.1.11) catalyses the phosphorylation of fructose 6-
phosphate (F6P) to fructose 1,6-bisphosphate (F16BP). PFK regulation is complex, befitting its role as
the first committed step of glycolysis. The extraordinarily ancient nature of this enzyme is reflected in
the melange of structural, kinetic, and regulatory properties found in PFKs of different species [1].
Vertebrate PFK monomers are approximately twice the size of bacterial counterparts, suggesting a
eukaryotic gene duplication and fusion process [2]. PFK gene duplication appears to have occurred
twice in certain eukaryotic lineages, even before the separation of the fungi [3], with vertebrate
genomes possessing three separate PFK genes, historically labelled as PFK-M (muscle), PFK-L (liver),
and PFK-P (platelet). With the exception of skeletal muscle, which only expresses PFK-M, human
tissues express all three PFK isoforms, though in varying ratios [4]; exact quantification of differential
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PFK expression in each tissue has not been attempted. In this paper we provide a detailed comparison of the
kinetic properties of each human isoform, placing this into the context of sequence and structural differences,
as well as isoform-specific transcript level changes between human tissues.
Mammalian PFKs are inactive as monomers and dimers, but active as tetramers [5]; heteromeric tetramers
(comprising more than one isoform) can form but their biological significance remains unknown [6].
Additionally, PFK-L can adopt a multimeric filamentous form [7]. PFK paralogues are remarkably similar in
mass and polypeptide length despite the hundreds of millions of years of evolution separating each isoform
(Table 1). A protein crystal structure of human PFK-P is available [8]; crystal structures for full length PFK-L
and PFK-M have yet to be published, though given the high levels of amino acid identity the architecture of all
three isoforms is likely to be conserved (Figure 1). The well characterised Escherichia coli PFK (EcPFK) and
Trypanosoma brucei PFK (TbPFK) crystal structures (PDB references 1PFK and 6SY7, respectively) possess a
single active site and a further, single, allosteric site per monomer: gene duplication and fusion in eukaryotes
therefore suggests mammalian PFKs should possess two active sites. However, analysis of published human
PFK structures indicate conversion of the active site of one of the duplicated genes into an allosteric site that
binds fructose 2,6-bisphosphate (F26BP) which acts as an allosteric activator. There is also a degree of sequence
conservation around the ADP or AMP allosteric sites observed in the EcPFK and TbPFK X-ray structures, with
phosphate binding observed in the N-terminal and C-terminal domains of each mammalian PFK protomer
meaning that mammalian PFK tetramers putatively contain 4 active sites and 12 allosteric sites (Figure 1A).
Human PFK activity is tightly controlled through multiple processes, including allosteric regulation. The
most potent natural activator is F26BP, which has no other known function in mammalian cells except inhib-
ition of the gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase-1). F26BP production is highly con-
trolled through the bi-functional enzyme PFK-2 (also known as FBPase-2, fructose bisphosphatase-2,
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) comprising numerous isoforms resulting from four
genes and multiple splice variants [9]. The isoform PFKFB3 favours the formation of F26BP and is an
anti-cancer drug target [10]. Aside from F26BP, the major activators of mammalian PFK are AMP and ADP,
with the major inhibitors being ATP, citrate, lactate, and acyl-CoA [11]. Multiple other modulators of PFK
activity have been described, including several commonly used drugs (Supplementary Table S1) and pH [12–
15]. PFK activity can also be altered by changes in the propensity of inactive monomers/dimers to coalescence
into active tetramers. Multiple influencers of oligomerisation status have been described, including cancer-
associated mutations [8], redox status [14], and allosteric effectors [15]. Post-translational modifications regu-
late PFK activity; for example, O-GlcNAc modification of Ser529 prevents F26BP binding, enhancing tumour
cell survival in hypoxic conditions [16]. Formation of metabolons (complexes of metabolic enzymes) also
change PFK activity by enabling channelling of glycolytic intermediates, ameliorating the limiting effects of dif-
fusion, and allowing PFK dimers to become active [17]. The regulatory differences between PFK isoforms, par-
ticularly with regard to allosteric modulators, have not been systematically explored until now, despite the
increasing evidence linking disturbances in glycolysis with diseases including Alzheimer’s disease [18], multiple
sclerosis [19], and cancer [20]. Previous studies have focussed on a single isoform, or at the most two isoforms,
and true comparative studies of the three isoforms are rare, often using partially purified tissue-derived
enzymes (Supplementary Table S10) [4,21,22]. Our results, which systematically characterise the differences
between human PFK isoforms in terms of kinetic properties, sequence and structural changes, and tissue-
specific transcript levels, help explain the different and specific roles played by each of the three PFK isoforms.
Methods
Production of human phosphofructokinases
Recombinant human PFKs were expressed in PFK-deficient Saccharomyces cerevisiae and purified using the
methods described previously [23], adapting earlier materials and protocols [24]. Production of PFK intended
for use in ATP titration experiments used 1 mM F6P as a tetramer stabilising agent in protein purification and
storage buffers. Production of PFK intended for use in F6P titration experiments used 1 mM ATP as a tetramer
stabilising agent in protein purification and storage buffers. Experimental details on the purification and char-
acterisation procedures including figures showing SDS–PAGE gels of the highly pure PFKs used in the kinetic
experiments described in this work have been recently published [23]. Western blots, and MALDI-TOF mass
spectrometry via in-gel and in-solution digests showed no evidence of N-linked glycosylation (data not shown)
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and addressed concerns over possible inappropriate glycosylation from the yeast expression system, which may
interfere with enzyme activity [16].
Determination of kinetic characteristics using ALDO-TIM-G3PDH
enzyme-linked kinetic assay
Assay buffer consisted of 50 mM TEA, 100 mM KCl, 10 mM MgCl2, 1 mM Tris(2-carboxyethyl)phosphine
hydrochloride (TCEP), 10% glycerol, pH 7.4. Assay mix consisted of 5 units/ml glycerol-3-phosphate dehydro-
genase (G3PDH, Sigma–Aldrich G6880), 2.5 units/ml aldolase (Sigma–Aldrich A2714), 25 units/ml triosepho-
sphate isomerase (TIM, Sigma–Aldrich T6258), and 1.25 mM NADH. ATP and F6P were obtained from
Sigma–Aldrich (A2383 and F3627, respectively). For ATP titrations, 38 ml of buffer or ligand were added to a
clear non-binding 96-well plate. 40 ml of assay mix containing 10 mM F6P (final concentration 4 mM) was
added and the plate was incubated at 25°C for 5 min. An amount of 2 ml of PFK isoforms were added to each
well from stock concentrations of 150 mg/ml and the reaction was immediately started with 20 ml of ATP at
varying concentrations. For F6P titrations, 30 ml of buffer or ligand was added to a clear non-binding 96-well
plate. An amount of 40 ml of assay mix containing 1.25 mM ATP (final concentration 0.5 mM) was added and
the plate was incubated at 25°C for 5 min. An amount of 5 ml of PFK isoforms were added to each well from
stock concentrations of 200 mg/ml and the reaction was immediately started with 20 ml F6P at varying concen-
trations. All ligands and substrates (including ATP) were used at pH 7.4. All metabolites were obtained from
Table 1 Comparison of human PFK-M, PFK-L and PFK-P sequences shows weak conservation
at Interface 2 residues compared with Interface 1 residues
PFK-M PFK-L PFK-P
PFK-M Overall identity - 69% 68%
- 780 AA Interface1 - 88% (58/66) 91% (60/66)
- 85.18 kDa Interface 2 - 63% (12/19) 79% (15/19)
ATP site - 88% (7/8) 100% (8/8)
F26BP site 84% (16/19) 95% (18/19)
Allosteric site A - 87% (13/15) 80% (12/15)
Allosteric site B - 88% (15/17) 82% (14/17)
PFK-L Overall identity 69% - 71%
- 780 AA Interface1 88% (58/66) - 89% (59/66)
- 85.02 kDa Interface 2 63% (12/19) - 58% (11/19)
ATP site 88% (7/8) - 88% (7/8)
F26BP site 84% (16/19) - 84% (16/19)
Allosteric site A 87% (13/15) - 67% (10/15)
Allosteric site B 76% (13/17) - 82% (14/17)
PFK-P Overall identity 68% 71% -
- 784 AA Interface1 91% (60/66) 89% (59/66) -
- 85.60 kDa Interface 2 79% (15/19) 58% (11/19) -
ATP site 100% (8/8) 88% (8/8) -
F26BP site 95% (18/19) 84% (16/19) -
Allosteric site A 80% (12/15) 67% (10/15) -
Allosteric site B 82% (14/17) 88% (15/17) -
Residues involved in Interface 1, Interface 2, and binding pockets for ATP and F26BP (Figure 1) were identified using
PDBePISA1 using the PFK-P structure (PDB 4XYJ). Allosteric sites A and B (Figure 1) were identified by overlying the
structure of EcPFK complex with ADP (PDB PFK1). Supplementary Table S2 compares Interface 1 amino acid
sequences; Supplementary Table S3 compares Interface 2 amino acid sequences.
1https://www.ebi.ac.uk/msd-srv/prot_int/pistart.html
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Figure 1. Models of PFK structures showing chain interface sites and allosteric binding sites. Part 1 of 2
Panel A shows the PFK-P tetrameric structure (PDB reference: 4XZ2) with the locations of the active sites and allosteric sites
indicated. Interface residues between protomer pairs were identified using PDBePISA. Interface 1 is between chains A (orange)
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4428
Biochemical Journal (2020) 477 4425–4441
https://doi.org/10.1042/BCJ20200656
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/22/4425/898266/bcj-2020-0656.pdf by U
K user on 01 D
ecem
ber 2020
Sigma–Aldrich unless otherwise stated. Ligand concentrations were chosen based on normal physiological con-
centrations (Supplementary Table S2) and ability to demonstrate effects above the signal-to-noise thresholds
for the enzyme-linked assay. A SpectraMax M5 Multi-Mode Microplate Reader was used to measure A340nm at
13 s intervals for 10 min. All experiments were performed in triplicate unless otherwise stated.
Time-dependent absorbance change was converted into rate of NADH oxidation (mM s−1) or specific activity
(mmol min−1 mg protein−1) using the Beer-Lambert law (molar extinction coefficient of NADH 6.22 mM−1
cm−1). The initial rate of reaction was used to avoid accumulation of ADP, which activates PFK, interfering
with the determination of kinetic properties. Non-linear regression analysis was performed on substrate titra-
tion data using GraphPad Prism 7, with curves fitted using allosteric sigmoidal models, enabling determination
of steady-state kinetic values.
Sequence and structure analysis
Output from PISA [25] using the coordinates from human PFK-P (PDB code 4xz2 [26]) was used to determine
those residues involved in interchain contacts across Interface 1 and Interface 2 and the binding pockets for
ATP and F26BP. All residues contributing a Buried Surface Area (BSA) value greater than 0.5 Å2 were selected
and compared with the equivalent residues in PFK-M and PFK-L
FANTOM5 data
The FANTOM5 database was interrogated for each of the enzymes of interest using the ZENBU visualisation
system. Phase 1 and 2 FANTOM5 data were used, containing hg19 assembly (Genome Reference Consortium
2009). All data used were RLE normalised and the robust dataset was preferred. The gene of interest was selected
and data in the direction of PFK gene transcription were examined, excluding time-course experimental data.
Tissue-specific data were identified from the appropriate promoters in the ‘FANTOM5 PHASE 1and2 FREEZE DPI
clusters human (robust set with expression)’ channel. Transcripts per million (TPM) scores were identified for each
sample, with samples categorised manually into tissue types and mean TPM scores calculated. Pearson correlation
coefficients of transcription were calculated for pairwise comparisons of PFK isoform with other metabolic enzymes.
Results and discussion
Biochemical comparison of human PFK isoforms
Kinetic parameters for PFK isoforms
PFK kinetic parameters values from all three human PFK isoforms were determined for ATP and F6P
(Table 2), derived from activity versus substrate concentration plots (Figure 2). PFK-M has high affinity for
F6P and ATP (K0.5
F6P 147 mM; K0.5
ATP 152 mM); PFK-L has low affinity for F6P but high affinity for ATP and F6P
(K0.5
F6P 1360 mM; K0.5
ATP 160 mM); PFK-P has low affinity for F6P and ATP (K0.5
F6P 1333 mM; K0.5
ATP 276 mM).
Cooperativity, as measured by Hill plot values, was absent for ATP titrations but present for F6P titrations:
PFK-L shows the most cooperativity (3.10), followed by PFK-P (2.18), and PFK-M the least (1.82). Specificity
constants (kcat
substrate/K0.5
substrate), a composite value amalgamating maximal activity and substrate affinity to
measure catalytic efficiency, showed PFK-M to be most efficient, followed by PFK-L, and then PFK-P (kcat
F6P/
K0.5
F6P 0.04, 0.002, 0.0009 s−1 mM−1, respectively; kcat
ATP/K0.5
ATP 0.37, 0.36, 0.14 s−1 mM−1, respectively). Differences
in maximal activity between F6P and ATP titrations are likely caused by changes in the order that substrates
are added to the assay mix (see Methods), as occurs in trypanosomatid PFKs [27]. Prolonged incubation with
F6P may favour the active tetramer form compared with incubation with ATP. These data are valid for the
Figure 1. Models of PFK structures showing chain interface sites and allosteric binding sites. Part 2 of 2
and B (cyan) (or C (purple) and D (yellow)). The view is along a pseudo 2-fold symmetry axis of the B/A dimer. There is an
equivalent symmetry related ‘interface 1’ between chains C and D. Interface 2 is between chains B and C (or the symmetry
related chains A and D). The active site of chain B shows F6P (red) and ADP (atom-type colour). The 4 molecules of F26BP in
green are close to Interface 2. Two ADP molecules (atom-type colour) are modelled into the remaining two allosteric sites of
chain B (cyan) labelled in Panel B as site A and site B. Panel B shows an overlay of EcPFK (PDB reference: 1PFK) and PFK-P
(cyan). Chain A of EcPFK (1PFK) fitted onto residues 1–384 of chain B of PFK-P is red and chain B of EcPFK (1PFK) fitted onto
residues 385–784 of chain B of PFK-P is raspberry. The allosteric binding sites A and B are occupied by ADP from the EcPFK
X-ray structure.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4429
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active tetrameric enzyme but it is known that PFK-L can form higher-order oligomers, including a filamentous
form [7]. These higher-order PFK-L oligomers may have significantly different kinetic properties with increased
affinity for F6P [28]. Similar effects are seen in the presence of PEG [29].
Titration of ATP concentrations (Figure 3), resulted in an initial increase in enzymatic activity with increas-
ing ATP concentrations before decreasing at higher ATP concentrations. Thus, the specific activity of PFK-M
increases 23% as ATP concentration increases from 0.25 mM to 0.5 mM ATP, but then decreases 21% as the
ATP concentration increases further from 0.5 mM to 1 mM ATP. Comparing the specificity constants for each
isoform at 0.5 mM and 1 mM ATP demonstrates that PFK-M is most resistant to ATP inhibition (21% decrease
at 1 mM ATP), PFK-L is intermediate (31% decrease), and PFK-P is most susceptible (50% decrease). This
hierarchy is the same as described previously in the literature [21,30]. High F6P concentrations relieved the
inhibitory effects of ATP, though to differing levels for each PFK isoform (Figure 3). Derived kinetic parameters
were highly dependent on experimental timings, in keeping with time and concentration-dependent enzyme
deactivation. This interpretation is valid for the conditions tested (pH 7.4) but may not hold true at other pH
values, with previous studies showing PFK-M activity being highly dependent on pH [12,13]. This caveat is
particularly important given muscle pH varies depending on time and intensity of muscle activity [31]. Results
from previous studies are shown in Supplementary Table S10A (Km
F6P) and 10B (Km
ATP); these indicate broadly
similar absolute results but differing hierarchies of activity for each isoform, which may relate to differences in
tissue purification and assay conditions, particularly regarding ATP, ADP, and other ligand concentrations.
Interestingly, we show that GTP is an alternative phospho donor for all three PFK isoforms, though resulting
in lower maximal velocity (Table 2). Previous studies have demonstrated binding of GTP to rabbit muscle PFK,
though kinetic data were lacking [32,33]. K0.5
GTP values showed each PFK isoform to have higher affinities for
GTP than ATP (PFK-M: 97 mM vs. 152 mM; PFK-L: 158 mM vs. 160 mM; PFK-P: 131 mM vs. 276 mM),
though comparison of specificity constants indicate that ATP is a more efficient substrate than GTP (0.37 vs.
0.27 s−1 mM−1; 0.36 vs. 0.23 s−1 mM−1; 0.14 vs. 0.14 s−1 mM−1, respectively). This raises the question of
whether GTP is a physiologically relevant substrate. The difference in intra-cellular GTP and ATP concentra-
tions (0.3 mM and 2.1 mM, respectively [34]), implies that PFK has a considerably greater capacity to sustain
glycolytic flux using ATP rather than GTP. Thus, under normal conditions, GTP is predicted to be less import-
ant than ATP, except in situations where GTP concentrations might exceed ATP concentrations.
Comparison of the amino acid sequences of the interface regions of the human
isoforms
We rationalised differences in kinetic behaviour by carrying out a detailed sequence comparison of the three
isoforms using the template provided by the X-ray structure of PFK-P (PDB 4xz2). The active tetramer is
Table 2 Human PFK isoforms display distinct kinetic properties
PFK-M PFK-L PFK-P
F6P Vmax
F6P (mmoles/min.mg) 5.56 (0.18) 3.69 (0.09) 1.26 (0.21)
K0.5
F6P (mM) 147.1 (13.6) 1360 (40) 1333 (312)
kcat
F6P (s−1) 8.11 (0.27) 5.38 (0.14) 1.83 (0.31)
kcat
F6P/K0.5
F6P (s−1 mM−1) 3.8 × 10−2 (1.32 × 10−2) 2.71 × 10−3 (2.25 × 10−3) 9.45 × 10−4 (6.73 × 10−4)
h (F6P) 1.82 (0.26) 3.10 (0.22) 2.18 (0.75)
ATP Vmax
ATP (mmoles/min.mg) 38.4 (0.9) 39.3 (1.2) 27.2 (2.5)
K0.5
ATP (mM) 151.8 (10.0) 160.1 (13.5) 275.6 (84.4)
kcat
ATP (s−1) 56.0 (1.2) 57.3 (1.7) 39.7 (1.7)
kcat
ATP/K0.5
ATP (s−1 mM−1) 0.37 (0.12) 0.36 (0.13) 0.14 (0.02)
h (ATP) 1.03 (0.05) 1.12 (0.08) 0.76 (0.09)
GTP Vmax
GTP (mmoles/min.mg) 17.82 (0.44) 25.39 (0.56) 12.30 (0.62)
K0.5
GTP (mM) 96.7 (8.0) 157.8 (10.8) 131 (20.9)
kcat
GTP (s−1) 26.0 (0.6) 37.0 (0.8) 17.9 (0.9)
kcat
GTP/K0.5
GTP (s−1 mM−1) 0.27 (0.08) 0.23 (0.07) 0.14 (0.04)
h (GTP) 1.19 (0.12) 1.18 (0.08) 1.12 (0.18)
Values are for kinetic properties determined by titrating the substrate listed in first column. For F6P titrations: ATP = 0.5 mM; n = 6. For ATP
titrations: F6P = 4 mM; n = 6. For GTP titrations: F6P = 4 mM; n = 3. Values are mean averages with standard deviations in parentheses.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4430
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formed by a dimer of dimers (Figure 1) with the A–B and C–D dimers held together by ‘Interface 1’ which has
∼40 hydrogen bonds including nine salt bridges. Each chain contributes an average buried surface area of ca.
2160 Å2 to this interface. The 66 residues that contribute more than 4 Å2 towards the buried surface area of
interface 1 are listed in Supplementary Table S3 and compared with equivalent sequences for PFK-L and
PFK-M. PFK-P differs from PFK-M by 6/66 residues (I90V, V91I, D448E being conservative, and A677S,
S571A, I476K not being conservative) and from PFK-L by 7/66 residues. PFK-L differs from PFK-M by 8/66
residues.
A similar analysis for Interface 2 shows that D–A (and B–C) interactions for PFK-P are stabilised by seven
hydrogen bonds incorporating four salt bridges, comprising interactions from 19 residues in total. Each chain
contributes an average of ca. 700 Å2 to this interface. Interestingly, it is this smaller interface that is conserved
in the dimeric X-ray structure of rabbit PFK-M that overlays very well with the human PFK-P structure (RMS
fits of 0.9 Å for monomer and 1.3 Å for dimer). The 19 residues that contribute more than 4 Å2 towards the
buried surface area of interface 2 are listed in Supplementary Table S4 and compared with equivalent sequences
in the PFK-L and PFK-M isoforms. There are 11/19 (58%) of residues conserved between PFK-P and PFK-L,
and 15/19 (79%) residues conserved between PFK-P and PFK-M at this interface. As discussed below, this
interface regulates the equilibrium between inactive dimer and active tetramer and is therefore key to under-
standing the differences in enzyme activity and allosteric behaviour of the isoforms.
Figure 2. PFK-L is as active as PFK-M with respect to ATP, but much less active with respect to F6P.
Panel A shows similar kinetic properties with respect to ATP titrations (F6P 4 mM) for PFK-M (blue squares with solid lines)
and PFK-L (red circles with dotted lines) with PFK-P (green triangles with dot-dash lines) showing lower activity. Panel B
shows PFK-M to be much more active than PFK-L or PFK-P with respect to F6P titrations (ATP 0.5 mM). (n = 6).
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4431
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Figure 3. The inhibitory effect of ATP differs between the three PFK isoforms.
Levels of ATP inhibition differ between PFK-M (panel A), PFK-L (panel B), and PFK-P (panel C), at ATP concentrations of
0.5 mM (blue squares with solid lines), 1 mM (red circles with dotted lines), and 2 mM (green triangles with dot-dash
lines). (n = 3). Note that y-axis scales differ between Panels.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4432
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Allosteric modulation of PFK activity by F26BP
F26BP strongly activated all three isoforms under the conditions tested, with AC50
F26BP values showing that
PFK-L was most sensitive (0.17 mM± 0.16), followed by PFK-M (6.27 mM± 1.57) and PFK-P (9.13 mM± 2.19)
(Supplementary Table S5). F26BP strikingly activates PFK-L at low to medium (physiological) concentrations
of F6P, and PFK-P at high concentrations of F6P (between 1 mM and 2 mM), with PFK-M showing a more
modest activation. In contrast, F26BP has little effect on kinetic properties for ATP titrations, except for PFK-P,
where the K0.5
ATP almost halves (Figure 4, Table 3, Supplementary Table S5). Thus, for ATP PFK-M is less sensi-
tive to F26BP allosteric modulation than PFK-L or PFK-P (allosteric constants [K0.5
ATP+F26BP/K0.5
ATP] 1.10, 0.92,
0.54, respectively). The use of coupled-enzyme assays is limited by potential effects of ligands on auxiliary
enzymes and accumulation of active metabolites (such as ADP in our assay). These effects were ameliorated by
the use of auxiliary enzyme in excess concentrations, and the lack of known allosteric effects of F26BP on any
auxiliary enzymes, as well as the use of the initial rate of reaction to calculate kinetic properties. Of the two pre-
vious comparative studies to investigate the effects of F26BP, both show a dramatic increase in F6P affinities in
the presence of F26BP, though there are differences in absolute values reported and the relative responses of
each isoform in comparison with other isoforms [4,21]. An isoform-specific comparison of how affinity for
ATP changes in the presence of F26BP has not been previously published.
Supplementary Table S6 compares the F26BP binding site in the three human isoforms. The F26BP pocket
is well conserved; out of the 19 residues that interact with F26BP, there is only one substitution (G584A)
between PFK-M and PFK-P. There are 3/19 differences between PFK-L and PFK-P isoforms (G584T, M583V
and V539I), which may help explain the >50-fold decrease in AC50
F26BP for PFK-L compared with PFK-P.
Figure 4B shows that PFK-L has a dramatic increase in activity at physiological concentrations of F6P when
low concentrations of F26BP are present, whereas PFK-P only shows a response at supra-physiological concen-
trations of F6P. This difference is postulated to be due to the differences in AC50
F26BP between PFK-L and
PFK-P. Previous analyses have shown that bound F26BP acts as a bridge to lock and tighten binding across the
A/B (and C/D) interfaces [35]. Nineteen residues binding F26BP were identified, with full conservation of the 5
residues (26%) involved in interactions across Interface 1 (Supplementary Table S6).
Allosteric modulation of PFK activity by AMP and ADP
With respect to ATP titrations, AMP has minimal effect on PFK-M, a modest effect on PFK-L, but causes a
marked increase in maximal activity and ATP affinity for PFK-P (Figure 4). For F6P titrations the effects are
even more striking: PFK-L is very strongly activated by AMP (more than 5-fold decrease in K0.5
F6P), PFK-P is
also activated (two-fold decrease in K0.5
F6P), but the near two-fold decrease in K0.5
F6P for PFK-M is offset by a con-
comitant reduction in Vmax
F6P leading to an overall decrease in catalytic efficiency (Figure 4, Table 3,
Supplementary Table S5). The effect of ADP is more complicated: inhibiting PFK-M, having mixed effects on
PFK-L, and activating PFK-P (Figure 4, Table 3, Supplementary Table S5). ADP markedly increases affinity for
F6P and Vmax
F6P for PFK-P and PFK-L, but markedly decreases Vmax
F6P for PFK-M. In contrast, ADP has little
effect on affinity for ATP for PFK-P, but decreases affinity for PFK-L and PFK-M. In contrast, GDP has a nega-
tive effect, causing a loss of affinity for ATP in all isoforms. As with all the results discussed, comparison of
these values to the published literature is challenging given the paucity of comparative studies, and differences
in enzyme purification (tissue derived vs. recombinant) and assay conditions (e.g. ATP concentrations).
The allosteric sites for the three isoforms were compared in order to explore how sequence differences might
explain the changes in AMP or ADP binding on enzyme activity (Supplementary Table S7). An overlay of the
EcPFK structure (PDB 1PFK) defines two allosteric sites (A and B) in each human PFK (hPFK) chain
(Figure 1). In EcPFK, ADP binds in a cleft between two chains, whereas in the PFK-P structure (PDB 4xz2)
these sites bind phosphate, which overlays very closely with the β-phosphate of the ADP bound to EcPFK. The
shape of this allosteric A-site pocket fits closely with the EcPFK pocket and there are no apparent steric restric-
tions to prevent fitting ADP for any of the three isoforms. In the A-site, there are 15 amino acids within 4 Å of
the docked ADP, with the key phosphate-binding residues (R430, R434) conserved between all human iso-
forms. Comparing these 15 residues, the PFK-L and PFK-M isoforms are most similar, while the PFK-L and
PFK-P isoforms are least similar (87% and 67% conservation of sequence identities, respectively). Site B com-
prises 17 residues within 4 Å of the docked ADP. There is an insertion of three residues in the three human
isoforms (627KTTIQR632), which matches structurally with the E. coli sequence (213KKH215) and results in
an additional bulge at the neck of the ADP binding pocket with Ile630 closing the entrance and potentially
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Figure 4. PFK-P activity is modulated more by allosteric regulators than PFK-M or PFK-L. Part 1 of 2
The effects of F26BP (10 mM) on ATP titrations (A) are less pronounced than on F6P titrations (B), as is found for AMP
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sterically hindering ADP binding. This tends to support the idea that the B-site may be more specific for
smaller or more flexible effector molecules like PEP or citrate.
The pattern for activation summarised in Table 3 shows the PFK-L and PFK-P isoforms are both strongly
activated by AMP and ADP, while PFK-M is slightly inhibited. AMP has a consistently greater effect than
ADP. There are two substitutions in the B-site that differentiate PFK-M from the PFK-P and PFK-L isoforms
(S571A and I630V) which may play a role in the difference in behaviour for PFK-M (Supplementary Table S7).
Allosteric modulation of PFK activity by citrate and PEP
The results presented here show considerable diversity of the effect of citrate on the different isoforms
(Figure 4, Table 3, Supplementary Table S5). There are marked dose-response effects for PFK-M (IC50
citrate 982
± 109 mM) and PFK-P (IC50
citrate 177 ± 132mM), but not PFK-L (no clear relationship). With respect to ATP,
maximal activity decreases (especially for PFK-P), but ATP affinities increase. A clear picture of inhibition is
demonstrated for F6P titrations, with decreasing maximal activities and increasing K0.5
F6P values. When specific
activities are considered, the overall impression is that citrate acts as an activator with regards to ATP (PFK-P
> PFK-L > PFK-M) at least at low (sub-physiological) ATP concentrations, but as an inhibitor with regards to
F6P (PFK-P > PFK-M > PFK-L). Thus, citrate is not simply the pure inhibitor described in the literature.
PEP, previously described as a PFK inhibitor, also has mixed effects (Table 3, Supplementary Table S5).
Although both PFK-M and PFK-L (but not PFK-P) show increased affinity for ATP in the presence of PEP,
the concomitant decrease in Vmax
ATP cancels this out, with just PFK-P showing a marked inhibitory effect when
specific activities are measured. Similarly, PFK-L and PFK-P (but not PFK-M) have decreased affinity for F6P
in the presence of PEP, but changes in Vmax
F6P mean that overall effects are negligible, except for a modest activat-
ing effect on PFK-L.
Figure 4. PFK-P activity is modulated more by allosteric regulators than PFK-M or PFK-L. Part 2 of 2
(1200 mM) on ATP (C) and F6P (D). ADP (600 mM) inhibits PFK-M and activates PFK-L and PFK-P for ATP titrations (E) and
F6P titrations (F). Citrate (600 mM) inhibits PFK-P for ATP titrations (G) and F6P titrations (H). PFK-M (blue squares with solid
blue lines), PFK-L (red circles with solid red lines), PFK-P (green triangles with solid green lines). Curves obtained in the
presence of allosteric modulators are given in equivalent dashed lines with open symbols. (n = 3, all values normalised to
highest respective control value).
Table 3 Summary of effects of various modulators of PFK activity on each
human PFK isoform
Metabolite PFK-M PFK-L PFK-P
AMP (1200 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) −12% +9% +220%
kcat
F6P/K0.5
F6P (s−1 mM−1) −25% +766% +162%
ADP (600 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) −52% −47% +39%
kcat
F6P/K0.5
F6P (s−1 mM−1) −13% +157% +129%
GDP (1100 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) +4.3% −48% −0.2%
kcat
F6P/K0.5
F6P (s−1 mM−1) ND ND ND
F26BP (10 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) −7.4% +6.5% +88%
kcat
F6P/K0.5
F6P (s−1 mM−1) +82% +148% +111%
Citrate (600 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) +5% +28% +136%
kcat
F6P/K0.5
F6P (s−1 mM−1) −36% +2% −78%
PEP (1100 mM) kcat
ATP/K0.5
ATP (s−1 mM−1) −11% +1% −40%
kcat
F6P/K0.5
F6P (s−1 mM−1) −7% +92% +9%
Effect of modulators with respect to ATP and F6P, as measured by percentage changes in
specificity constants compared with control PFK without modulator (absolute values in Table 2).
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Published studies have shown that mutations of PFK-M in the B-allosteric site (K567R, D601V and K627A,
amino acid numbering conforming to Supplementary Table S7) preserved wild-type activity but were much
less sensitive to the inhibitory effect of citrate [36]. Electron microscopy has been used to show that citrate pro-
moted dissociation of wild-type PFK-P tetramers into dimers [8]. Another study showed that the cancer-
associated mutation R48C reduced the inhibitory effect of citrate 10-fold. An earlier study also showed that
another mutation of this phosphate-binding residue (R48L) abolished the inhibitory effects of citrate on rabbit
PFK-M [37]. All four residues in these mutational studies are conserved across the M, L and P isoforms,
strongly indicating that the B-site (Supplementary Table S7) is a conserved allosteric binding site for citrate.
The observation that the R48L mutation had a slightly positive effect on the allosteric activity of ADP or AMP
[37] further supports the idea that the B-site is regulated by citrate and possibly smaller metabolites while the
A-site (Figure 1) is regulated by AMP and ADP [36].
The marked effects of citrate on PFK-P compared with the more modest effects on PFK-L and PFK-M
(Figure 4, Table 3, Supplementary Table S5) may be explained by differences in amino acid sequences in the
B-site. The 17 amino acids lining the citrate-binding B-site are conserved among the three isoforms by 76%–
88%, with only one amino acid S84M (PFK-M) and S84N (PFK-L) uniquely non-conserved (Supplementary
Table S7). Intra-cellular concentrations of F6P are generally far lower than ATP (e.g. 0.11 mM F6P in human
muscle and 5.1 mM ATP in rat cardiomyocytes [34,38]), leading to the conclusion that citrate typically acts as
an inhibitor under physiological conditions.
The role of tetramer thermal stability and PFK enzyme activity
The enzymatic activity of PFK-M declined rapidly in a concentration and time-dependent fashion
(Supplementary Figure S1) in the absence of substrates (F6P or ATP) or reducing agent (TCEP). Storage at 4°C
for 24 h led to a decrease in PFK-M activity to 52% of baseline when stored at a concentration of 0.32 mg/ml,
and to 19% at 0.16 mg/ml, and 7% at 0.08 mg/ml. The decline in activity was inversely proportional to concen-
tration. Addition of substrates (F6P or ATP) or reducing agents (TCEP or dithiothreitol, DTT) reduced the loss
of activity. Simultaneous addition of substrate and a reducing agent to PFK-M concentrations above 0.1 mg/ml
resulted in complete protection against inactivity, though concentrations below 0.1 mg/ml still lost activity over
time (data not shown). Thermal denaturation assays demonstrated protein stability also correlated with protein
concentration (data not shown). PFK-M tetramer was most stable in size-exclusion chromatography, but both
PFK-L and PFK-P showed broad retention peaks with trailing edges, in keeping with on-column dissociation;
PFK-P was especially susceptible to on-column dissociation, with markedly overlapping tetramer and dimer
peaks (Supplementary Figure S2). Taken together, these results suggest a hierarchy of isoform stability with dif-
ferent rate constants for time-dependent dissociation: PFK-M being most stable, then PFK-L, and finally
PFK-P.
These results showing the clear correlation between enzyme activity and tetramer stability are consistent with
previously published data that used light scattering to measure the dimer-tetramer equilibrium for PFK-M [5].
Electron microscopy has also been used to directly visualise the dimer and tetramer populations of PFK-P, with
a mutation (F649L) that weakens Interface 2 and may result in an increased proportion of dimers over tetra-
mers (Supplementary Table S4) [8]. The mechanism by which allosteric modulators affect PFK activity remains
uncertain. Previous studies describe how various modulators affect activity including activation by F26BP,
ADP, and phosphate, and inhibition by high ATP concentrations and citrate [5,8,39]. The precise mechanism
by which this occurs is unknown, and it remains up for debate; whether it is due to direct stabilisation/destabil-
isation of the tetramer/dimer/monomer states; whether it is due to changes in the conformational equilibria of
the tetramer between R-state and T-state; or whether it is a combination of the two mechanisms.
In the comparative study of the three paralogous PFKs presented here, we show that PFK-P and PFK-L are
highly sensitive to AMP and ADP activation, with PFK-M being much less affected. Interestingly, the trypano-
somatid PFKs show similar disparate behaviour that is explained by differences in thermal stability: Leishmania
infantum PFK (LiPFK) has a remarkable response to AMP compared with the related Trypanosoma brucei and
Trypanosoma cruzi PFKs [27]. In the case of LiPFK the AMP response was linked to a dramatic increase in
protein stability (as measured by thermal stability), favouring the formation of active tetramers, and preventing
dissociation into inactive dimers. This is analogous to the allosterically regulated PFK-P and PFK-L isoforms,
which are regulated (stabilised) by AMP/ADP binding to the allosteric A-site in the N and C-domains
(Figure 1, Supplementary Table S7, and Supplementary Table S8).
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Specialised biological roles of the M, L and P isoforms
Transcript profiles of PFK isoforms show differential transcription according to tissue
type
Transcript profiles of the three PFK isoforms differed greatly between the 21 tissue types included in the
FANTOM-5 database (Figure 5A). Total transcript per million (TPM) scores demonstrate PFK-P transcripts to
be the most abundant (106,128), followed by PFK-L (46,641) and PFK-M the least (23,454). This hierarchy
Figure 5. PFK isoforms show tissue specific dynamic differences in transcript levels.
(A) Mean average TPM values for each group of FANTOM-5 samples were compared for each isoform. Certain tissues contain
more PFK transcripts than other tissues e.g. renal, endothelium, and eye. Proportions of each isoform follow the general
hierarchy of PFK-P > PFK-L > PFK-M, though with notable exceptions e.g. immune cells and skeletal muscle. Liver data are
included under ‘Gut’ heading, and shows: 47.2% PFK-L; 47.1% PFK-P; 5.6% PFK-M. (B,C) PFK-P transcription overtakes
PFK-L in monocyte-derived macrophages exposed to LPS (Panel B) and Influenza A (Panel C), with PFKFB3 correlating with
PFK-P. PFK-M (blue squares with solid lines); PFK-L (red circles with dotted lines); PFK-P (green triangles with
dashed lines); PFKFB3 (orange diamonds with dot-dashed lines). Lines are segmented lines of best fit, errors bars are
standard deviations, n = 3 for LPS and n = 4 for influenza.
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(PFK-P > PFK-L > PFK-M) is found in most tissue types, except for brain and cardiac tissue (PFK-P > PFK-M
> PFK-L), skeletal muscle (PFK-M > PFK-P > PFK-L), and immune cells (PFK-L > PFK-P > PFK-M). Liver cells
show an equal predominance of PFK-L and PFK-P, with a much smaller contribution from PFK-M. The inter-
pretation of these results is limited by the lack of full correlation between transcript profiles and protein levels,
which are influenced by transcriptional efficiency, transcript stability, and protein turnover, amongst other
factors, as shown by the cytoskeletal-mediated ubiquitin-dependent proteasomal degradation of PFK [40] and
quantitative proteomic studies [41]. Correlation with semi-quantitative proteomic data was performed using the
Human Tissue Atlas, which uses commercially available isoform-specific antibodies [42]. These data confirm
that PFK-M and PFK-P are expressed at greater levels compared with PFK-L.
In immune cells, PFK-M transcripts are virtually absent, with the predominant isoform being
PFK-L. Activation of monocyte-derived macrophages by lipopolysaccharide (LPS) or Influenza A results in dra-
matic changes in PFK isoform transcript levels (Figure 5B,C). PFK-P is up-regulated by LPS (10.3× baseline)
and Influenza A (13.8×); PFKFB3 transcript levels closely mirror PFK-P. In contrast, PFK-L transcript levels
increase modestly after LPS stimulation (1.9× baseline) and decrease to negligible levels after Influenza A infec-
tion. Active immune cells require large amounts of energy for the ATP-dependent process of cell membrane
movement (phagocytosis) and for the NADPH-dependent respiratory burst and production of neutrophil
extracellular traps, both dependent on glycolysis and glutaminolysis [43,44]. Thus, the switch from PFK-L at
rest to PFK-P during activation is a strong clue to the differing functions of each isoform. The relative insensi-
tivity of PFK-P to ATP inhibition would permit high enzymatic activity irrespective of cellular ATP concentra-
tions, as opposed to PFK-L which is more responsive to ATP inhibition.
Correlations between transcript levels of metabolic enzymes show cancer-related
changes
Transcript levels of PFK-L and PFK-P were positively correlated in non-cancer tissues (r = 0.68, P = 7.1 × 10−4),
but there was no statistically significant relationship between either of these isoforms and PFK-M. This suggests
that PFK-P and PFK-L are not ‘rivals’ but instead work together, having different metabolic roles within cells.
This links to the kinetic and regulatory properties of each isoform: since PFK-P is responsive in low ATP con-
ditions, and PFK-L in low F6P conditions, expressing both simultaneously will expand the metabolic capacity
for the F6P to F16BP reaction under varying conditions. PFK-M alone would have the same capacity but lacks
the regulatory activity of the other two isoforms, particularly with regards to activation by F26BP. In cancer
tissues, the correlation between PFK-L and PFK-P becomes non-significant (r = 0.14, P = 0.39), suggesting that
cancer tissues have a more binary approach to PFK expression, prioritising one isoform over another. Full cor-
relation coefficients are shown in Supplementary Tables S9A,B. An alternate explanation for the positive correl-
ation between PFK-L and PFK-P transcript levels is that either or both isoforms have ‘moonlighting’ functions
— secondary cellular roles distinct from that in glycolysis. Moonlighting functions are found in many glycolytic
enzymes [45,46], including PFK-P, which also acts as a co-transcriptional regulator of YAP/Taz and an activa-
tor of PI3K [47,48]. Increased transcript levels may therefore relate to non-glycolytic functions.
In non-cancerous tissues, transcript levels of PFK-P correlate highly (0.67) with the pyruvate kinase (PYK)
isoenzymes M1 and M2 (PKM1/2). In cancerous tissues this is the only strong correlation to be preserved
among the glycolytic enzymes. This analysis does not distinguish between the M1 and M2 PYK isoforms,
although previous studies have shown that it is the allosterically regulated M2 splice variant form that is preva-
lent in cancer tissues [20]. Our work highlights several interesting similarities between PYK and PFK — long
regarded as the key regulators of the glycolytic pathway. Of the two forms of PYK-M, M1 is constitutively
active — analogous to PFK-M — whereas M2 is allosterically regulated (by F16BP) through dissociation of
active tetramers into inactive dimers/monomers [49], analogous to the behaviour of PFK-P (and PFK-L), which
are allosterically regulated by F26BP preventing dissociation of active tetramers into inactive dimers/monomers.
Interestingly it is the highly allosterically regulated forms of both PFK (PFK-P) and PYK (PKM2) that are
up-regulated in cancer cells, presumably allowing glycolysis to work efficiently when nutrients are available but
also shut down rapidly in response to changes in metabolite concentration.
The relationship between PFKFB3, responsible for synthesis of F26BP, the most potent enhancer of PFK activ-
ity, and PFK-P differs in non-cancer and cancer tissues. In non-cancerous tissues there is a negative correlation
between transcripts levels of these enzymes, suggesting a regulatory mechanism that limits overall PFK activity
(high expression of PFK is counteracted by lower F26BP levels). In cancer tissues there is a loss of this potential
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feedback mechanism: transcript levels of PFK and PFKFB3 are positively correlated. This highlights the physio-
logical relevance of the highly activating effect of F26BP demonstrated in the kinetic experiments above and may
provide an explanation for why PFK-P — the isoform most strongly activated by F26BP — is most up-regulated
in cancers. LDH-A, another cancer-associated enzyme, also positively correlates with PFK-P [50,51].
The position of glucose-6-phosphate dehydrogenase (G6PDH) as the entry-point to the anabolic pentose-
phosphate pathway (PPP) means that transcript levels of this enzyme could be expected to negatively correlate
with downstream glycolytic enzyme transcript levels. However, the correlation data indicate the reverse:
G6PDH is positively correlated with most glycolytic enzymes, including PFK-L and PFK-P (r = 0.64, P = 2 ×
10−3; r = 0.47, P = 0.03, respectively). There is no correlation between G6PDH and PFKFB3 (which increases
glycolytic activity through activation of PFK), suggesting a lack of antagonism between the PPP and glycolytic
pathways. This supports the concept that there is not a binary choice between glycolysis and the PPP: what
occurs may be an up-regulation of both pathways at the same time. Thus, the cell may literally both have its
cake (making new cellular building blocks) and eat it (making energy available), an idea currently in vogue
[52]. These correlations are not found in cancer samples, suggesting prioritisation of single pathways in cancer
tissues.
Conclusions
In this paper we present the first systematic comparison of recombinant human PFK isoforms. Intrinsic differ-
ences in substrate affinities for each isoform were demonstrated. PFK-M is the most active enzyme but is much
less versatile than the other isoforms, being unable to respond to allosteric modulation to the degree shown by
PFK-L and PFK-P, especially with regard to F26BP activation and ATP inhibition. Comparison of the amino
acid sequences of the three isoforms using published X-ray structures supports the idea that variations in
isoform activity and regulation are linked to tetrameric stability at the key dimer-dimer interface (Interface 2
[Figure 1]), which controls the active tetramer to inactive dimer equilibrium.
The biological rationale for these structural and kinetic differences evolving and persisting was explored by
investigating tissue-specific transcript levels of each isoform. PFK-M, which is most active but least regulated, is
the predominant isoform in skeletal muscle, where there is a constant need for ATP production. Brain and
cardiac muscle, which also have high baseline ATP requirements, also express high levels of PFK-M, whereas
PFK-P is the dominant isoform in most tissues, highlighting the importance of activity modulation by allosteric
regulators.
Extending these comparisons to include cancer-derived samples reveals further insights into the role of PFK.
Transcript levels of PFK-P strongly correlate with PYK isoforms in both non-cancerous and cancer samples,
with intriguing similarities between PFK-M and PKM1 (highly active, poorly regulated), and also between
PFK-P and PKM2 (lower activity, greater regulation). It is the highly regulated low activity isoforms — PFK-P
and PKM2 — that are associated with cancer samples, indicating that for some cancers glycolytic regulation
may be of greater importance than activity.
CRediT Contribution
Malcolm D. Walkinshaw: Conceptualization, Resources, Formal analysis, Funding acquisition, Project
administration, Writing — review and editing. Peter M. Fernandes: Conceptualization, Investigation, Writing —
original draft, Writing — review and editing. James R. Kinkead: Conceptualization, Investigation, Methodology,
Writing — original draft. Iain W. McNae: Investigation, Methodology. Paul A. Michels: Conceptualization,
Writing — original draft, Writing — review and editing.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Funding
P.M.F. was funded by the Wellcome Trust [grant number 106359]. J.K. was funded by a Wellcome Trust Seeding
Drug Discovery grant. Further funding from MRC Confidence in Concept grant.
Open Access
Open access for this article was enabled by the participation of University of Edinburgh in an all-inclusive Read
& Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4439
Biochemical Journal (2020) 477 4425–4441
https://doi.org/10.1042/BCJ20200656
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/22/4425/898266/bcj-2020-0656.pdf by U
K user on 01 D
ecem
ber 2020
Author Contributions
All authors were involved in the conception of the work, the interpretation of the data and the preparation of the
manuscript. Experiments were performed by P.M.F. and J.K. All authors approved the manuscript.
Acknowledgements
We thank Professor J. Heinisch (Universität Osnabrück) for the donation of the vector pJJH71 and the double
PFK knockout strain of S. cerevisiae. We thank Professor Kim Summers for assistance with the FANTOM5
database. We thank Dr Li-Hsuan Yen, Ms Giulia Romanelli, and the Edinburgh Protein Production Facility (Dr
Martin Wear, Dr Elizabeth Blackburn, and Dr Matt Nowicki) for assistance with recombinant protein production
and characterisation, and Dr Jimi Wills with mass spectrometry data collection.
Abbreviations
EcPFK, Escherichia coli PFK; F16BP, fructose 1,6-bisphosphate; F26BP, fructose 2,6-bisphosphate; G6PDH,
glucose-6-phosphate dehydrogenase; LPS, lipopolysaccharide; LiPFK, Leishmania infantum PFK; PFK,
6-Phosphofructokinase-1-kinase; PKM2, pyruvate kinase M2; PPP, pentose-phosphate pathway; PYK, pyruvate
kinase; TCEP, Tris(2-carboxyethyl)phosphine hydrochloride; TPM, Transcripts per million; TbPFK, Trypanosoma
brucei PFK.
References
1 Fothergill-Gilmore, L.A. and Michels, P.A.M. (1993) Evolution of glycolysis. Prog. Biophys. Mol. Biol. 59, 105–235 https://doi.org/10.1016/0079-6107
(93)90001-Z
2 Bapteste, E., Moreira, D. and Philippe, H. (2003) Rampant horizontal gene transfer and phospho-donor change in the evolution of the
phosphofructokinase. Gene 318, 185–191 https://doi.org/10.1016/S0378-1119(03)00797-2
3 McNae, I.W., Martinez-Oyanedel, J., Keillor, J.W., Michels, P.A.M., Fothergill-Gilmore, L.A. and Walkinshaw, M.D. (2009) The crystal structure of
ATP-bound phosphofructokinase from Trypanosoma brucei reveals conformational transitions different from those of other phosphofructokinases. J. Mol.
Biol. 385, 1519–1533 https://doi.org/10.1016/j.jmb.2008.11.047
4 Dunaway, G., Kasten, T.P., Sebo, T. and Trapp, R. (1988) Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem. J.
251, 677–683 https://doi.org/10.1042/bj2510677
5 Zancan, P., Marinho-Carvalho, M.M., Faber-Barata, J., Dellias, J.M.M. and Sola-Penna, M. (2008) ATP and fructose-2,6-bisphosphate regulate skeletal
muscle 6-phosphofructo-1-kinase by altering its quaternary structure. IUBMB Life 60, 526–533 https://doi.org/10.1002/iub.58
6 Vora, S., Seaman, C., Durham, S. and Piomelli, S. (1980) Isozymes of human phosphofructokinase: identification and subunit structural characterization
of a new system. Proc. Natl Acad. Sci. U.S.A. 77, 62–66 https://doi.org/10.1073/pnas.77.1.62
7 Webb, B.A., Dosey, A.M., Wittmann, T., Kollman, J.M. and Barber, D.L. (2017) The glycolytic enzyme phosphofructokinase-1 assembles into filaments.
J. Cell Biol. 216, 2305–2313 https://doi.org/10.1083/jcb.201701084
8 Webb, B.A., Forouhar, F., Szu, F., Seetharaman, J., Tong, L. and Barber, D.L. (2016) Structures of human phosphofructokinase-1 and atomic basis of
cancer-associated mutations. Nature 523, 111–114 https://doi.org/10.1038/nature14405
9 Rider, M.H., Bertrand, L., Vertommen, D., Michels, P.A., Rousseau, G.G. and Hue, L. (2004) 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase:
Head-to-head with a bifunctional enzyme that controls glycolysis. Biochem. J. 381, 561–579 https://doi.org/10.1042/BJ20040752
10 Neal, J.O., Clem, A., Reynolds, L., Dougherty, S., Imbert-fernandez, Y., Telang, S. et al. (2016) Inhibition of 6-phosphofructo-2-kinase (PFKFB3)
suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res. Treat. 160, 29–40 https://doi.org/10.1007/
s10549-016-3968-8
11 Nakajima, H., Raben, N., Hamaguchi, T. and Yamasaki, T. (2002) Phosphofructokinase deficiency; past, present and future. Curr. Mol. Med. 2,
197–212 https://doi.org/10.2174/1566524024605734
12 Trivedi, B. and Danforth, W.H. (1966) Effect of pH on the kinetics of frog muscle phosphofructokinase. J. Biol. Chem. 241, 4110–4114 PMID:4224144
13 Frieden, C., Gilbert, H.R. and Bock, P.E. (1976) Correlation of the regulatory kinetic and molecular properties of the rabbit muscle enzyme. J. Biol.
Chem. 251, 5644–5647 PMID:9395
14 Walters, D.W. and Gilbert, F. (1986) Thiol/disulfide exchange between rabbit muscle phosphofructokinase and glutathione. J. Biol. Chem. 261,
15372–15377 PMID:2946673
15 Schöneberg, T., Kloos, M., Brüser, A., Kirchberger, J. and Sträter, N. (2013) Structure and allosteric regulation of eukaryotic 6-phosphofructokinases.
Biol. Chem. 394, 977–993 https://doi.org/10.1515/hsz-2013-0130
16 Yi, W., Clark, P.M., Mason, D.E., Keenan, M.C., Hill, C., William, A. et al. (2013) PFK1 glycosylation is a key regulator of cancer cell growth and central
metabolic pathways. Science 337, 975–980 https://doi.org/10.1126/science.1222278
17 Marcondes, M.C., Sola-Penna, M., Gianoti, S. and Zancan, P. (2011) Muscle-type 6-phosphofructo-1-kinase and aldolase associate conferring catalytic
advantages for both enzymes. IUBMB Life 63, 435–445 https://doi.org/10.1002/iub.464
18 Atlante, A., de Bari, L., Bobba, A. and Amadoro, G. (2017) A disease with a sweet tooth: exploring the Warburg effect in Alzheimer’s disease.
Biogerontology 18, 301–319 https://doi.org/10.1007/s10522-017-9692-x
19 Paling, D., Golay, X., Wheeler-Kingshott, C., Kapoor, R. and Miller, D. (2011) Energy failure in multiple sclerosis and its investigation using MR
techniques. J. Neurol. 258, 2113–2127 https://doi.org/10.1007/s00415-011-6117-7
20 Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R. et al. (2008) The M2 splice isoform of pyruvate kinase is
important for cancer metabolism and tumour growth. Nature 452, 230–233 https://doi.org/10.1038/nature06734
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4440
Biochemical Journal (2020) 477 4425–4441
https://doi.org/10.1042/BCJ20200656
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/22/4425/898266/bcj-2020-0656.pdf by U
K user on 01 D
ecem
ber 2020
21 Meienhofer, M.C., Cottreau, D., Dreyfus, J.C. and Kahn, A. (1980) Kinetic properties of human F4 phosphofructokinase. FEBS Lett. 110, 219–222
https://doi.org/10.1016/0014-5793(80)80077-9
22 Moreno-Sánchez, R., Marin-Hernandez, A., Gallardo-Perez, J.C., Quezada, H., Encalada, R., Rodriguez-Enriquez, S. et al. (2012) Phosphofructokinase
type 1 kinetics, isoform expression, and gene polymorphisms in cancer cells. J. Cell. Biochem. 113, 1692–1703 https://doi.org/10.1002/jcb.24039
23 Fernandes, P.M., Kinkead, J.R., McNae, I.W., Bringaud, F., Michels, P.A.M. and Walkinshaw, M.D. (2019) The kinetic characteristics of human and
trypanosomatid phosphofructokinases for the reverse reaction. Biochem. J. 476, 179–191 https://doi.org/10.1042/BCJ20180635
24 Heinisch, J. (1986) Construction and physiological characterization of mutants disrupted in the phosphofructokinase genes of Saccharomyces cerevisiae.
Curr. Genet. 11, 227–234 https://doi.org/10.1007/BF00420611
25 Krissinel, E. and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 https://doi.org/10.1016/
j.jmb.2007.05.022
26 Kloos, M., Bruser, A., Kirchberger, J., Schoneberg, T. and Strater, N. (2015) Crystal structure of human platelet phosphofructokinase-1 locked in an
active conformation. Biochem. J. 469, 421–432 https://doi.org/10.1042/BJ20150251
27 Fernandes, P.M., Kinkead, J., McNae, I.W., Wear, M.A., Michels, P.A.M. and Walkinshaw, M.D. (2020) Kinetic and structural studies of Trypanosoma
and Leishmania phosphofructokinases show evolutionary divergence and identify AMP as a switch regulating glycolysis versus gluconeogenesis. FEBS J.
13, 2847–2861 https://doi.org/10.1111/febs.15177
28 Reinhart, G.D. and Lardy, H.A. (1980) Rat liver phosphofructokinase: kinetic and physiological ramifications of the aggregation behavior. Biochemistry
19, 1491–1495 https://doi.org/10.1021/bi00548a036
29 Reinhart, G.D. and Hartleip, S.B. (1987) Perturbation of the quaternary structure and allosteric behavior of rat liver phosphofructokinase by polyethylene
glycol. Arch. Biochem. Biophys. 258, 65–76 https://doi.org/10.1016/0003-9861(87)90323-7
30 Dunaway, G.A. and Kasten, T.P. (1988) Physiological implications of the alteration of 6-phosphofructo-1-kinase isozyme pools during brain development
and aging. Brain Res. 456, 310–316 https://doi.org/10.1016/0006-8993(88)90233-8
31 Street, D., Bangsbo, J. and Juel, C. (2001) Interstitial pH in human skeletal muscle during and after dynamic graded exercise. J. Physiol. 537,
993–998 https://doi.org/10.1113/jphysiol.2001.012954
32 Ogawa, Y. and Atkinson, D.E. (1985) Interactions between citrate and nucleoside triphosphates in binding to phosphofructokinase. Biochemistry 24,
954–958 https://doi.org/10.1021/bi00325a022
33 Liou, R.S. and Anderson, S.R. (1978) Binding of ATP and of 1,N6-ethenoadensone triphosphate to rabbit muscle phosphofructokinase. Biochemistry 17,
999–1004 https://doi.org/10.1021/bi00599a009
34 Traut, T.W. (1994) Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1–22 https://doi.org/10.1007/BF00928361
35 Banaszak, K., Mechin, I., Obmolova, G., Oldham, M., Chang, S.H., Ruiz, T. et al. (2011) The crystal structures of eukaryotic phosphofructokinases from
baker’s yeast and rabbit skeletal muscle. J. Mol. Biol. 407, 284–297 https://doi.org/10.1016/j.jmb.2011.01.019
36 Usenik, A. and Legisa, M. (2010) Evolution of allosteric citrate binding sites on 6-phosphofructo-1-kinase. PLoS ONE 5, e15447 https://doi.org/10.
1371/journal.pone.0015447
37 Li, Y., Rivera, D., Ru, W., Gunasekera, D. and Kemp, R.G. (1999) Identification of allosteric sites in rabbit phosphofructo-1-kinase. Biochemistry 38,
16407–16412 https://doi.org/10.1021/bi991761l
38 Fersht, A. (1999) Structure and Mechanism in Protein Science, 2nd ed, WSPC
39 Hesterberg, L.K. and Lee, J.C. (1982) Self-association of rabbit muscle phosphofructokinase: effects of ligands. Biochemistry 21, 216–222 https://doi.
org/10.1021/bi00531a003
40 Park, J.S., Burckhardt, C.J., Lazcano, R., Solis, L.M., Li, L., Chen, C.S. et al. (2020) Mechanical regulation of glycolysis via cytoskeleton architecture.
Nature 578, 621–626 https://doi.org/10.1038/s41586-020-1998-1
41 Jiang, L., Wang, M., Lin, S., Jian, R., Li, X., Chan, J. et al. (2019) A quantitative proteome map of the human body. Cell 183, 269–283.e19
https://doi.org/10.1016/j.cell.2020.08.036
42 Fagerberg, L., Hallstro, M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J. et al. (2014) Analysis of the human tissue-specific expression by
genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 13, 397–406 https://doi.org/10.1074/mcp.M113.
035600
43 Furukawa, S., Saito, H., Matsuda, T., Inoue, T., Fukatsu, K., Han, I. et al. (2000) Relative effects of glucose and glutamine on reactive oxygen
intermediate production by neutrophils. Shock 13, 274–278 https://doi.org/10.1097/00024382-200004000-00004
44 Rodríguez-Espinosa, O., Rojas-Espinosa, O., Moreno-Altamirano, M.M.B., López-Villegas, E.O. and Sánchez-García, F.J. (2015) Metabolic requirements
for neutrophil extracellular traps formation. Immunology 145, 213–224 https://doi.org/10.1111/imm.12437
45 Gómez-Arreaza, A., Acosta, H., Quiñones, W., Concepción, J.L., Michels, P.A.M. and Avilán, L. (2014) Extracellular functions of glycolytic enzymes of
parasites: unpredicted use of ancient proteins. Mol. Biochem. Parasitol. 193, 75–81 https://doi.org/10.1016/j.molbiopara.2014.02.005
46 Kim, J.W. and Dang C, V. (2005) Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 30, 142–150 https://doi.org/10.1016/j.tibs.2005.01.
005
47 Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M. et al. (2015) Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO
J. 34, 1349–1370 https://doi.org/10.15252/embj.201490379
48 Lee, J., Liu, R., Li, J., Wang, Y., Tan, L., Li, X.J. et al. (2018) EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation.
Mol. Cell 70, 197–210 https://doi.org/10.1016/j.molcel.2018.03.018
49 Morgan, H.P., O’Reilly, F.J., Wear, M.A., O’Neill, J.R., Fothergill-Gilmore, L.A., Hupp, T. et al. (2013) M2 pyruvate kinase provides a mechanism for
nutrient sensing and regulation of cell proliferation. Proc. Natl Acad. Sci. U.S.A. 110, 5881–5886 https://doi.org/10.1073/pnas.1217157110
50 Atsumi, T., Chesney, J., Metz, C., Leng, L., Donnelly, S., Makita, Z. et al. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,
6-bisphosphatase. Cancer Res. 62, 5881–5887 PMID:12384552
51 Fantin, V.R., St-Pierre, J. and Leder, P. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 9, 425–434 https://doi.org/10.1016/j.ccr.2006.04.023
52 DeBerardinis, R.J. and Chandel, N.S. (2020) We need to talk about the Warburg effect. Nat. Metab. 2, 127–129 https://doi.org/10.1038/
s42255-020-0172-2
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4441
Biochemical Journal (2020) 477 4425–4441
https://doi.org/10.1042/BCJ20200656
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/22/4425/898266/bcj-2020-0656.pdf by U
K user on 01 D
ecem
ber 2020
